Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Prothena

DB:0PT
Snowflake Description

Excellent balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
0PT
DB
$413M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The last earnings update was 34 days ago. More info.


Add to Portfolio Compare Print
  • Prothena has significant price volatility in the past 3 months.
0PT Share Price and Events
7 Day Returns
19.3%
DB:0PT
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-6.4%
DB:0PT
-13.2%
DE Biotechs
-20.9%
DE Market
0PT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Prothena (0PT) 19.3% 6.3% -23.3% -6.4% -77.6% -70.5%
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • 0PT outperformed the Biotechs industry which returned -13.2% over the past year.
  • 0PT outperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
0PT
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Prothena's competitors could be found in our database.

0PT Value

 Is Prothena undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Prothena to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Prothena.

DB:0PT Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 7 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.2%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:0PT
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 6.5%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.19
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.188 (1 + (1- 12.5%) (5.55%))
1.165
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.16
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.165 * 6.51%)
7.19%

Discounted Cash Flow Calculation for DB:0PT using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Prothena is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:0PT DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.19%)
2020 -80.61 Analyst x1 -75.20
2021 -86.93 Analyst x2 -75.66
2022 -93.00 Analyst x1 -75.51
2023 -68.00 Analyst x1 -51.51
2024 35.00 Analyst x1 24.73
2025 48.50 Est @ 38.57% 31.97
2026 61.53 Est @ 26.88% 37.84
2027 73.04 Est @ 18.7% 41.91
2028 82.52 Est @ 12.97% 44.17
2029 89.91 Est @ 8.96% 44.90
Present value of next 10 years cash flows $-52.00
DB:0PT DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $89.91 × (1 + -0.39%) ÷ (7.19% – -0.39%)
$1,181.35
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,181.35 ÷ (1 + 7.19%)10
$589.90
DB:0PT Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $-52.00 + $589.90
$537.90
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $537.90 / 39.91
$13.48
DB:0PT Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:0PT represents 0.9855x of NasdaqGS:PRTA
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.9855x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 13.48 x 0.9855
€13.28
Value per share (EUR) From above. €13.28
Current discount Discount to share price of €10.20
= -1 x (€10.20 - €13.28) / €13.28
23.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Prothena is available for.
Intrinsic value
23%
Share price is €10.2 vs Future cash flow value of €13.28
Current Discount Checks
For Prothena to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Prothena's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Prothena's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Prothena's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Prothena's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:0PT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.95
NasdaqGS:PRTA Share Price ** NasdaqGS (2020-04-03) in USD $10.35
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Prothena.

DB:0PT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:PRTA Share Price ÷ EPS (both in USD)

= 10.35 ÷ -1.95

-5.31x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Prothena is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Prothena is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Prothena's expected growth come at a high price?
Raw Data
DB:0PT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.31x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
19.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Prothena, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Prothena's assets?
Raw Data
DB:0PT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $6.84
NasdaqGS:PRTA Share Price * NasdaqGS (2020-04-03) in USD $10.35
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:0PT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:PRTA Share Price ÷ Book Value per Share (both in USD)

= 10.35 ÷ 6.84

1.51x

* Primary Listing of Prothena.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Prothena is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Prothena's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Prothena has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

0PT Future Performance

 How is Prothena expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
19.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Prothena expected to grow at an attractive rate?
  • Prothena's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Prothena's earnings growth is expected to exceed the Germany market average.
  • Prothena's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:0PT Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:0PT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 19.4%
DB:0PT Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 52.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:0PT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:0PT Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 131 38 0 3
2023-12-31 70 -65 -31 4
2022-12-31 14 -88 -95 4
2021-12-31 19 -84 -96 7
2020-12-31 6 -79 -94 7
2020-04-06
DB:0PT Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 1 -53 -78
2019-09-30 1 -60 -79
2019-06-30 1 -84 -84
2019-03-31 1 -14 -128
2018-12-31 1 -28 -156
2018-09-30 1 -47 -181
2018-06-30 1 -31 -209
2018-03-31 27 -125 -167
2017-12-31 28 -131 -153
2017-09-30 27 -125 -154
2017-06-30 28 -138 -145
2017-03-31 1 -129 -168

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Prothena's earnings are expected to grow by 19.4% yearly, however this is not considered high growth (20% yearly).
  • Prothena's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:0PT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from Prothena Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0PT Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -0.13 1.41 -1.54 3.00
2023-12-31 -1.07 -0.29 -1.97 3.00
2022-12-31 -2.03 -1.25 -2.55 4.00
2021-12-31 -2.21 -1.07 -3.66 7.00
2020-12-31 -2.25 -2.07 -2.57 7.00
2020-04-06
DB:0PT Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.95
2019-09-30 -1.97
2019-06-30 -2.10
2019-03-31 -3.21
2018-12-31 -3.93
2018-09-30 -4.61
2018-06-30 -5.38
2018-03-31 -4.34
2017-12-31 -4.07
2017-09-30 -4.21
2017-06-30 -4.07
2017-03-31 -4.83

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Prothena will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Prothena's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Prothena has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

0PT Past Performance

  How has Prothena performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Prothena's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Prothena does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Prothena's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Prothena's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Prothena's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Prothena Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0PT Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 0.81 -77.68 35.74
2019-09-30 0.75 -78.58 35.70
2019-06-30 0.80 -83.70 36.25
2019-03-31 0.91 -127.77 38.16
2018-12-31 0.96 -155.65 42.48
2018-09-30 0.99 -180.94 48.50
2018-06-30 0.95 -208.78 51.70
2018-03-31 27.49 -166.60 51.62
2017-12-31 27.52 -153.24 48.23
2017-09-30 27.46 -154.38 35.09
2017-06-30 27.53 -145.23 38.78
2017-03-31 1.05 -167.97 36.01
2016-12-31 1.06 -160.11 32.36
2016-09-30 1.19 -135.36 38.08
2016-06-30 1.33 -115.10 27.85
2016-03-31 1.28 -92.93 25.24
2015-12-31 1.61 -80.61 23.11
2015-09-30 3.31 -69.57 21.49
2015-06-30 4.37 -59.77 19.81
2015-03-31 19.21 -40.20 19.23
2014-12-31 50.85 -7.15 19.05
2014-09-30 49.01 -5.09 19.31
2014-06-30 47.69 -1.60 18.47
2014-03-31 32.74 -14.19 16.74
2013-12-31 0.68 -41.00 15.05
2013-09-30 1.08 -42.16 12.74
2013-06-30 1.86 -41.14 11.44

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Prothena has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Prothena has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Prothena improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Prothena's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Prothena has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

0PT Health

 How is Prothena's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Prothena's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Prothena is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Prothena's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Prothena's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Prothena has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Prothena Company Filings, last reported 3 months ago.

DB:0PT Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 272.92 0.00 375.72
2019-09-30 289.18 0.00 390.30
2019-06-30 302.81 0.00 398.14
2019-03-31 312.13 0.00 410.11
2018-12-31 323.00 0.00 427.66
2018-09-30 339.65 0.00 451.51
2018-06-30 356.01 0.00 486.21
2018-03-31 409.51 0.00 429.04
2017-12-31 407.19 0.00 417.62
2017-09-30 446.25 0.00 456.06
2017-06-30 486.98 0.00 471.73
2017-03-31 496.25 0.00 506.55
2016-12-31 365.40 0.00 386.92
2016-09-30 401.10 0.00 408.57
2016-06-30 430.87 0.00 442.95
2016-03-31 465.78 0.00 474.25
2015-12-31 360.67 0.00 370.59
2015-09-30 377.95 0.00 387.80
2015-06-30 395.22 0.00 402.39
2015-03-31 277.43 0.00 279.86
2014-12-31 289.89 0.00 293.58
2014-09-30 301.56 0.00 306.15
2014-06-30 298.42 0.00 303.85
2014-03-31 193.01 0.00 195.05
2013-12-31 173.27 0.00 176.68
2013-09-30 98.78 0.00 101.86
2013-06-30 107.23 0.00 112.51
  • Prothena has no debt.
  • Prothena has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Prothena has sufficient cash runway for more than 3 years based on current free cash flow.
  • Unable to confirm if Prothena has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Prothena's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Prothena has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

0PT Dividends

 What is Prothena's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Prothena dividends. Estimated to be 0% next year.
If you bought €2,000 of Prothena shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Prothena's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Prothena's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:0PT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:0PT Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-04-06

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Prothena has not reported any payouts.
  • Unable to verify if Prothena's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Prothena's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Prothena has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Prothena's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Prothena's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Prothena afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Prothena has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

0PT Management

 What is the CEO of Prothena's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Gene Kinney
COMPENSATION $3,213,354
AGE 50
TENURE AS CEO 3.6 years
CEO Bio

Mr. Gene G. Kinney, Ph.D., has been the Chief Executive Officer and President of Prothena Corporation plc since September 26, 2016 and October 3, 2016 respectively and served as its Chief Operating Officer since September 06, 2016 until October 20, 2016. Mr. Kinney served as a Chief Scientific Officer and Head of Research & Development at Prothena Corporation plc from December 2012 to October 03,2016. Prior to that, Mr. Kinney was senior vice president of pharmacological sciences (a position he held from 2011 to 2012), and vice president, pharmacology (a position he held from 2009 to 2012) for elan pharmaceuticals, inc; while in those positions, Mr. Kinney also served as head of nonclinical research for janssen alzheimer immunotherapy r&d. from 2001 to 2009, Mr. Kinney was senior director, head of central pharmacology and acting lead for bioanalytics & pathology at the merck research laboratories, where he contributed to the strategic direction and oversight of drug discovery activities and led a number of non-clinical discovery and clinical development programs targeted for the treatment of neurodegenerative and psychiatric conditions. Mr. Kinney has been Director at Prothena Corporation plc since September 2016. Mr. Kinney also held positions at bristol-myers squibb and was an assistant professor at the emory university school of medicine, department of psychiatry and behavioral sciences. Mr. Kinney holds BA from bloomsburg university and his MA and PhD from florida atlantic university.

CEO Compensation
  • Gene's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Gene's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Prothena management team in years:

2.8
Average Tenure
50
Average Age
  • The tenure for the Prothena management team is about average.
Management Team

Gene Kinney

TITLE
President
COMPENSATION
$3M
AGE
50
TENURE
3.6 yrs

Tran Nguyen

TITLE
CFO & COO
COMPENSATION
$2M
AGE
45
TENURE
7.1 yrs

Michael Malecek

TITLE
Chief Legal Officer & Company Secretary
COMPENSATION
$2M
AGE
53
TENURE
0.8 yrs

Carol Karp

TITLE
Chief Regulatory Officer
COMPENSATION
$1M
AGE
66
TENURE
3.3 yrs

Radhika Tripuraneni

TITLE
Chief Development Officer
COMPENSATION
$1M
AGE
39
TENURE
2.3 yrs

Karin Walker

TITLE
Chief Accounting Officer & Controller
AGE
56
TENURE
6.9 yrs

Wagner Zago

TITLE
Chief Scientific Officer
COMPENSATION
$3M
AGE
46
TENURE
2.8 yrs

Ellen Rose

TITLE
Head of Communications

Brandon Smith

TITLE
Chief Business Officer
AGE
44
TENURE
0.1 yrs

Marty Koller

TITLE
Consultant
COMPENSATION
$2M
AGE
68
TENURE
2.2 yrs
Board of Directors Tenure

Average tenure and age of the Prothena board of directors in years:

6.8
Average Tenure
63
Average Age
  • The tenure for the Prothena board of directors is about average.
Board of Directors

Lars Ekman

TITLE
Independent Chairman
COMPENSATION
$212K
AGE
69
TENURE
7.3 yrs

Gene Kinney

TITLE
President
COMPENSATION
$3M
AGE
50
TENURE
3.6 yrs

Richard Collier

TITLE
Independent Director
COMPENSATION
$192K
AGE
65
TENURE
7.3 yrs

Shane Cooke

TITLE
Independent Director
COMPENSATION
$193K
AGE
57
TENURE
7.3 yrs

Paula Cobb

TITLE
Independent Director
COMPENSATION
$277K
AGE
46
TENURE
0.8 yrs

Chris Henney

TITLE
Independent Director
COMPENSATION
$188K
AGE
78
TENURE
7.1 yrs

Dennis Selkoe

TITLE
Independent Director
COMPENSATION
$194K
AGE
75
TENURE
6.8 yrs

Karl Anders Härfstrand

TITLE
Independent Director
COMPENSATION
$178K
AGE
63
TENURE
5.3 yrs

Oleg Nodelman

TITLE
Independent Director
AGE
42
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Prothena's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Prothena has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

0PT News

Simply Wall St News

0PT Company Info

Description

Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson’s disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta, a protein for the treatment of Alzheimer’s disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegeneration. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Celgene Corporation to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.

Details
Name: Prothena Corporation plc
0PT
Exchange: DB
Founded: 2012
$382,886,748
39,911,413
Website: http://www.prothena.com
Address: Prothena Corporation plc
77 Sir John Rogerson’s Quay,
Block C,
Dublin,
Co. Dublin, 2,
Ireland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS PRTA Ordinary Shares Nasdaq Global Select US USD 18. Dec 2012
DB 0PT Ordinary Shares Deutsche Boerse AG DE EUR 18. Dec 2012
LSE 0Y3M Ordinary Shares London Stock Exchange GB USD 18. Dec 2012
Number of employees
Current staff
Staff numbers
51
Prothena employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 00:28
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/04/03
Last earnings filing: 2020/03/03
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.